Activation syndrome
Activation syndrome is a form of stimulation (sometimes suicidal) or agitation that has been observed in association with some psychoactive drugs.[1] A causative role has not been established.[2] Pfizer has denied that sertraline can cause such effects.[3][4]
Treatment
[edit]Serotonin reuptake inhibitors (SSRI) have been associated with a state of restlessness, lability, agitation, and anxiety termed "activation syndrome". In some people, this state change can increase suicidal tendencies, especially in those under age 25 and during the initial weeks of treatment.[2] SSRI-induced activation syndrome is well-accepted by clinicians.[5] It is unclear whether jitteriness/anxiety syndrome predicts either good or poor prognosis (level D). [6]
References
[edit]- ^ "Recent regulatory 2006" (PDF). Archived from the original (PDF) on 2011-07-08. Retrieved 2010-06-14.
- ^ a b "www.accessdata.fda.gov" (PDF).
- ^ "Pfizer letter to Healy" (PDF). healyprozac.com. Retrieved 8 April 2023.
- ^ "Archived copy" (PDF). Archived from the original (PDF) on 2010-12-23. Retrieved 2010-06-14.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ Reid JM, Storch EA, Murphy TK, Bodzin D, Mutch PJ, Lehmkuhl H, Aman M, Goodman WK (2010). "Development and Psychometric Evaluation of the Treatment-Emergent Activation and Suicidality Assessment Profile". Child Youth Care Forum. 39 (2): 113–124. doi:10.1007/s10566-010-9095-5. PMC 2867356. PMID 20473344.
- ^ Lindsey I. Sinclair; David M. Christmas; Sean D. Hood; John P. Potokar; Andrea Robertson; Andrew Isaac; Shrikant Srivastava; David J. Nutt; Simon J.C. Davies (2009). "Antidepressant-inducedjitteriness/anxiety syndrome:systematicreview". The British Journal of Psychiatry. 194 (6): 483–490. doi:10.1192/bjp.bp.107.048371. PMID 19478285.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |